Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Drug-induced extrapyramidal disorders]

J F Horga1, M Navarro, V Peiró

  • 1Programa de Fármacovigilancia de la Communidad Valenciana, Conselleria de Sanidad y Consumo, Valencia.

Revista De Neurologia
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variations of pharmacokinetics of drugs in patients with cirrhosis.

Expert review of clinical pharmacology·2015
Same author

Polypodium leucotomos extract in atopic dermatitis: a randomized, double-blind, placebo-controlled, multicenter trial.

Actas dermo-sifiliograficas·2012
Same author

Ketanserin potentiates morphine-induced antinociception mediated by kappa-receptor activation.

Pharmacological research·2011
Same author

The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports.

Alimentary pharmacology & therapeutics·2010
Same author

Women's health and gender-based clinical trials on etoricoxib: methodological gender bias.

Journal of public health (Oxford, England)·2009
Same author

Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards.

Pharmacological research·2008
Same journal

The Correlation Between and Variability of Three Balance Scales in the Assessment of Balance Function in Patients With Ataxia.

Revista de neurologia·2026
Same journal

Surgical Treatment of an Aneurysm in the Subacute Stage of Hemorrhagic Moyamoya Disease: Aneurysm Resection Combined With STA-MCA Bypass: A Case Report.

Revista de neurologia·2026
Same journal

Mapping the Evidence: Central Sleep Apnea Syndromes During Sleep and Stroke-A Scoping Review.

Revista de neurologia·2026
Same journal

Developmental and Epileptic Encephalopathy Due to a Novel <i>ARHGEF9</i> Deletion Variant: Case Series of Two Siblings.

Revista de neurologia·2026
Same journal

P300 Event-Related Potentials as Cognitive Biomarkers in Neurological and Neuropsychiatric Disorders: A Systematic Review.

Revista de neurologia·2026
Same journal

[Effectiveness and Risk of Recurrence of Pulsed Radiofrequency in Trigeminal Neuralgia and Chronic Cluster Headache].

Revista de neurologia·2026
See all related articles

Calcium-entry blockers and benzamides are linked to drug-induced parkinsonism. This study analyzed 402 adverse events, finding these drug classes and specific patient demographics, predominantly females, are frequently associated with movement disorders.

Area of Science:

  • Pharmacovigilance
  • Neurology
  • Clinical Pharmacology

Context:

  • Analysis of 402 drug-adverse events submitted to the Spanish Pharmacovigilance System until 1994.
  • Focus on movement disorders and parkinsonism aggravation.
  • Investigates patient demographics and associated drug classes.

Purpose:

  • To identify patient characteristics associated with drug-induced parkinsonism.
  • To determine the specific drugs linked to these adverse events.
  • To assess the prevalence and characteristics of parkinsonism in pharmacovigilance data.

Summary:

  • Calcium-entry blockers (31%) and benzamides (27%) were the most frequently implicated drug groups.
  • Adverse events predominantly affected females and occurred in age intervals of 11-30 and 60-80 years.

Related Experiment Videos

  • Approximately 80% of the reported events were classified as serious.

    • Impact:

    • Suggests a high prevalence of drug-related parkinsonism.
    • Recommends considering the role of calcium-entry blockers in drug-induced parkinsonism during prescription.
    • Underscores the importance of pharmacovigilance in identifying drug-induced neurological adverse events.